GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (XCNQ:DMED) » Definitions » Debt-to-EBITDA

Diagnamed Holdings (XCNQ:DMED) Debt-to-EBITDA : 0.00 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Diagnamed Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Diagnamed Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$0.00 Mil. Diagnamed Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$0.00 Mil. Diagnamed Holdings's annualized EBITDA for the quarter that ended in Sep. 2024 was C$-0.59 Mil. Diagnamed Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Diagnamed Holdings's Debt-to-EBITDA or its related term are showing as below:

XCNQ:DMED's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Diagnamed Holdings Debt-to-EBITDA Historical Data

The historical data trend for Diagnamed Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnamed Holdings Debt-to-EBITDA Chart

Diagnamed Holdings Annual Data
Trend Sep21 Sep22 Sep23 Sep24
Debt-to-EBITDA
- - - -

Diagnamed Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diagnamed Holdings's Debt-to-EBITDA

For the Health Information Services subindustry, Diagnamed Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnamed Holdings's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnamed Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Diagnamed Holdings's Debt-to-EBITDA falls into.



Diagnamed Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Diagnamed Holdings's Debt-to-EBITDA for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.741
=0.00

Diagnamed Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.592
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Diagnamed Holdings  (XCNQ:DMED) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Diagnamed Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Diagnamed Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagnamed Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Executives
Fabio Chianelli Director, Senior Officer

Diagnamed Holdings Headlines

No Headlines